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The polymorphism rs35767 at IGF1 
locus is associated with serum urate 
levels
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Previous studies suggested that the IGF-1/IGF-1 receptor signaling pathway may contribute to 
regulate uric acid levels. To confirm this hypothesis, we assessed the effects of the IGF-1-raising genetic 
variant rs35767 on urate levels in serum and urine, and we investigated IGF-1 ability to modulate the 
expression of transporters involved in reabsorption and secretion of uric acid in the kidney. The study 
population included 2794 adult Whites. 24-hour urinary uric acid concentration was available for 229 
subjects. rs35767 polymorphism was screened using TaqMan genotyping assays. HEK293 (human 
embryonic kidney-293) cell line was treated with IGF-1 (1, 5, 10, 50 nM) for 24-hours, and differences in 
the expression of urate transporters were evaluated via Western Blot and real time rtPCR. Individuals 
carrying the IGF-1-raising allele (rs35767 T) exhibited significantly lower levels of serum urate according 
to both additive and recessive models, after correction for gender, age, BMI, glucose tolerance, 
glomerular filtration rate, and anti-hypertensive treatment. TT genotype carriers displayed higher 
uricosuria than C allele carriers did, after adjusting for confounders. Exposure of HEK293 cells to IGF-1 
resulted in a dose-dependent increase of uric acid transporters deputed to uric acid excretion (MRP4, 
NPT1 and BCRP), and reduction of GLUT9 expression, the major mediator of uric acid reabsorption, 
both at mRNA and protein level. We observed a significant association between the functional 
polymorphism rs35767 near IGF1 with serum urate concentrations and we provide a mechanistic 
explanation supporting a causal role for IGF-1 in the regulation of uric acid homeostasis.
Uric acid is a final breakdown product of purine degradation and circulates in the blood as urate. Concentrations of 
serum urate are increasing worldwide, owing in part to dietary and lifestyle factors, and rising prevalence of obesity, 
metabolic syndrome, impaired glucose tolerance/type 2 diabetes, insulin resistance, chronic kidney disease, and cardi-
ovascular diseases, all of which are associated with hyperuricemia1–11. Serum urate levels depend on the homeostasis 
between uric acid production, mainly from purine degradation in the liver, and its removal via the kidney and gut. 
Elevated serum urate levels are attributable to the net reabsorption of filtered uric acid in the proximal tubules12. In 
addition to the environmental factors, it has been estimated that heritability accounts for 40−70% of serum urate con-
centration variability13,14. A number of genome-wide association studies (GWAS) have so far identified 28 genomic 
loci associated with urate concentrations at genome-wide level of significance, and gout15–23. Notably, one of these loci 
associated with uric acid concentrations and gout was the intronic rs6598541 SNP located within IGF1R encoding 
for the receptor of insulin-like growth factor 1 (IGF-1)22,23, and the allele of the rs6598541 SNP associated with higher 
serum urate concentrations (0.043 mg/dl increase [CI 0.031–0.055], P = 5 × 10−15) was also found to be associated with 
lower fractional excretion of uric acid (β = −0.059% increase [s.e. = 0.019], P = 1.5 × 10–3)22. Interestingly, we have 
shown an inverse relationship between circulating IGF-1 and urate levels in nondiabetic adult subjects24 consistent 
with a prior pilot experimental study showing that IGF-1 acutely decreases serum urate concentration25, thus suggest-
ing that the IGF-1/IGF-1 receptor signaling pathway plays a role in regulating serum urate levels.
In order to verify this hypothesis, we decided to assess the association of a functional polymorphism (rs35767) 
located within the promoter of the IGF1 gene with urate levels in adult subjects of European ancestry. Prior studies 
have demonstrated that individuals carrying the T allele at rs35767 exhibit increased levels of circulating IGF-1 as com-
pared with CC carriers26–31. Therefore, we interrogated the NHGRI-EBI GWAS Catalog database32 and we consulted 
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the publicly accessible collection of complete results from the network analysis accomplished by Köttgen A. et al. in 
December 201222 to investigate if this polymorphisms affecting IGF-1 gene expression was associated with serum 
urate levels. Two polymorphisms in close proximity with rs35767, rs35765 and rs855214 (each scoring r2 = 0.74 in the 
CEU population of the HapMap project), were nominally associated with serum urate levels (P = 0.013 and P = 0.026, 
respectively), although this association did not reach genome-wide significance (P < 5 × 10−8).
To further clarify the impact of rs35767 on serum urate levels, we addressed its effects on circulating urate 
concentrations by screening a large cohort of well-characterized adult White Europeans. One potential explana-
tion for how IGF-1/IGF-1 receptor signaling pathway might contribute to regulate serum urate levels might be 
its ability to modulate expression of transporters involved in reabsorption and secretion of uric acid in the kid-
ney. Therefore, we examined the in vitro effect of IGF-1 on renal expression of uric acid transporters in Human 
Embryonic Kidney (HEK293) cells.
Materials and Methods
Study subjects. We analyzed 2794 unrelated individuals consecutively recruited at the Department of 
Medical and Surgical Sciences of the University “Magna Graecia” of Catanzaro and at the Department of Systems 
Medicine of the University of Rome-Tor Vergata as previously described33,34. The criteria for recruitment were: 
presence of at least one cardio-metabolic risk factor including but not limited to family history of diabetes, dysgly-
cemia/type 2 diabetes, hypertension, dyslipidemia, and overweight/obesity. Patients were excluded from the study 
if they had: gout, history of malignant diseases, end stage renal disease, heart failure, gastrointestinal affections 
with bleeding or malabsorption, anemia, hemoglobinopathies, hemolytic disease, autoimmune disorderss, acute 
or chronic infections, pancreatitis, accumulation diseases such as amyloidosis and hemochromatosis, history of 
drug abuse, self-reporting alcohol consumption of >20 g⁄day, positivity for antibodies to hepatitis C virus (HCV) 
or hepatitis B surface antigen (HBsAg), and corticosteroids use.
All patients were seen in the morning, after an overnight fast. In these circumstances information concerning 
medical history, drug use, and alcohol consumption were collected, anthropometrical parameters were recorded 
(i.e. body mass index (BMI), waist circumference, clinic blood pressure, etc.) and a sample of venous blood was 
drawn for laboratory determinations. A 75 g OGTT was carried out in subjects with no history of type 2 diabetes 
with sampling for plasma glucose determination. Twenty-four-hour urinary uric acid concentrations were meas-
ured concurrently on the day of blood sampling in 229 individuals.
The study was approved by the Institutional Ethics Committees of the University Magna Graecia of Catanzaro 
and the University of Rome Tor Vergata. All patients signed a written informed consent prior entering the study, 
in accordance with the principles of the Declaration of Helsinki.
Biochemical determinations. Serum urate levels were measured by the URICASE/POD method imple-
mented in an autoanalyzer (Boehringer Mannheim, Mannheim, Germany). Glucose concentrations were 
measured by enzymatic methods (Hoffman-La Roche, Basel, Switzerland). Glycated hemoglobin (HbA1c) was 
assessed by high performance liquid chromatography employing a National Glycohemoglobin Standardization 
Program (NGSP) certified automated analyzer (Adams HA-8160 HbA1C analyzer, Menarini, Italy). Serum cre-
atinine concentrations were assessed by an automated technique based on a Creatinine Jaffè compensated method 
for serum (Roche Diagnostics) implemented in an auto-analyzer.
rs35767 genotyping. Genomic DNA was extracted from whole peripheral blood using a commercial DNA 
purification kit (Promega, Madison, WI). rs35767 genotype calls were determined with TaqMan allelic discrimi-
nation assay (Assay ID# C__799146_10; Applied Biosystems, Foster City, CA). Template DNA was amplified and 
fluorescence was detected on an iCycler Thermal Cycler with iQ5 Multicolor Real-Time PCR Detection System 
(Bio-Rad Laboratories, Inc., Hercules, CA). Good genotyping quality was ensured by including 3 HapMap sam-
ples in each 96- well plate. Genotyping concordance of HapMap controls was >99%.
Cell culture and treatment. HEK293 (human embryonic kidney cell line) were grown in complete high 
glucose Dulbecco’s Modified Eagles’s Medium (DMEM, Sigma-Aldrich, Milan, Italy) supplemented with 10% 
(vol/vol) fetal bovine serum and 1% (vol/vol) penicillin/streptomycin, and maintained in a humidified atmos-
phere of 5% CO2 in air at 37 °C. For experiments cells were treated with IGF-1 (Sigma-Aldrich, Milan, Italy) at 
different concentration (1, 5, 10, 50 nM) for 24 h.
RNA extraction and real time PCR. After IGF-1 treatment, total RNA was extracted from HEK293 by 
Trizol reagent (Life Technologies, Gaithersburg, MD, USA) and reverse transcribed using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). mRNA expression of ABCG2 (BCRP, 
Hs01053790_m1), ABCC4 (MRP4, Hs00988717_m1), SLC17A1 (NPT1, Hs00192656_m1), SLC2A9 (GLUT9, 
Hs00417125_m1), SLC22A11 (OAT4, Hs00945829_m1) and SLC22A12 (URAT1, Hs00375985_m1) was analyzed 
by quantitative Real-Time PCR technique using TaqMan pre-designed gene-expression assays (Thermo Fisher 
Scientific, Waltham, MA, USA) on iQ5 real-time thermocycler (Bio-Rad, Hercules, CA, USA). Results were nor-
malized to the housekeeping gene 18S (Hs03928989_g1). All reactions were performed in triplicate. Relative gene 
expression was calculated by using the comparative CT (Livak) method. All reagents were obtained from Life 
Technologies Italia (Monza, Italy).
Western blot analysis. HEK293 proteins were extracted by lysing cells in buffer containing 50 mmol/L 
HEPES (pH 7.5), 150 mmol/L NaCl, 10 mmol/L EDTA, 1% Triton X-100, 10 mmol/L Na4P2O7, 100 mmol/L NaF, 
and 2 mmol/L sodium orthovanadate supplemented with protease inhibitors cocktail. Protein concentration was 
determined with the Bradford assay (DC Protein Assay; Bio-Rad, Hercules, CA) according to the manufacturer’s 
instructions.
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Equal amounts of proteins were resolved by SDS-PAGE and electrotransferred to nitrocellulose mem-
brane (Amersham Biosciences, Piscataway, NJ). Membranes were blocked with TBS with 5% milk accord-
ing to antibodies’ producers instructions, then probed with primary antibodies followed by incubation with 
peroxidase-conjugated secondary antibodies. Proteins were detected by using enhanced chemiluminescence 
(Amersham Biosciences, Piscataway, NJ), and band densities were quantified by densitometry using ImageJ soft-
ware. To normalize the blots for protein levels, after being immunoblotted with specific antibodies, the mem-
branes were probed with beta-actin antibody.
Reagents. HEK293 were purchased from ATCC (American Type Culture Collection, Manassas, USA). 
Media, sera and antibiotics for cell culture were from Sigma (Walkersville, MD, USA). Protein electrophore-
sis and western blot reagents were from Bio-Rad (Richmond, VA, USA) and electrochemiluminescence rea-
gents from Pierce (Rockford, IL, USA). IGF-1 was purchased from Thermo Fisher Scientific. The antibodies 
used were: anti-BCRP (ABCG2-ATP binding cassette subfamily G member 2) (Abbiotec, LCC, Dunbrook Rd, 
Ste A, San Diego, USA), anti-NPT1 (SLC17A1-solute carrier family 17 member 1) (Millipore, Burlington, 
Massachusetts, Stati Uniti), anti-MRP4 (ABCC4-ATP binding cassette subfamily C member 4) (Abcam, 
Cambridge, UK), anti-GLUT9a (SLC2A9-solute carrier family 2 member 9, protein isoform 1) (Novus Biologicals, 
Littleton, Colorado, USA), anti-OAT4 (SLC22A11-solute carrier family 22 member 11) (Abcam, Cambridge, 
UK), anti-URAT1 (SLC22A12-solute carrier family 22 member 12) (Abnova, Taiwan) and β-actin (R&D Systems, 
Minneapolis, Minnesota, USA).
Calculations. Study participants were categorized in accordance with their glucose tolerance status as NGT 
(normal glucose tolerance) when their fasting plasma glucose and 2-h post-challenge levels were <126 mg/dl and 
<140 mg/dl, respectively; IGT (impaired glucose tolerance) when fasting plasma glucose was <126 mg/dl and 2 h 
post-load was 140–199 mg/dl; type 2 diabetes when fasting plasma glucose was ≥126 mg/dl and/or 2 h post-load 
was >200 mg/dL. BMI was calculated as the ratio of weight in kg to the square of height in m. The MDRD equa-
tion [eGFR = 175 × (serum creatinine)−1.154 × (Age)−0.203 × (0.742 if female)] was employed to estimate glomer-
ular filtration rate (eGFR)35.
Statistical analysis. Continuous variables are summarized as means ± SD. Comparisons of continuous var-
iables within genotype groups were adjusted for confounding factors such as age, gender and BMI by ANCOVA 
(general linear model). Categorical variables were compared by χ2-test. In order to estimate the independent 
contribution of the rs35767 polymorphism to serum urate levels, we performed a linear regression analysis in a 
model which also included gender, age, and BMI. Genotype distributions were in Hardy Weinberg equilibrium 
(P > 0.05). Power calculations were performed with Quanto version 1.2.4 (http://hydra.usc.edu/gxe; accessed 25 
July 2011). The study had 98% power (for α = 0.05) to detect a 0.2 mg/dL change in serum urate levels per allele T. 
All tests were two-sided, and a P value < 0.05 was considered statistically significant. All analyses were performed 
using SPSS 22.0 (Chicago, IL, USA) software for Windows.
Data availability statement. All relevant data, materials and information is included in the manuscript.
Results
Table 1 summarizes anthropometrical and biochemical parameters of our population according to the genotype 
at rs35767. The association of the variant rs35767 with patients’ clinical features was analyzed according to an 
additive and a recessive genetic model (Table 1). The distribution of age, gender, BMI, waist circumference, sys-
tolic and diastolic blood pressure, fasting and 2 h post-load plasma glucose, HbA1c, glucose tolerance status, and 
eGFR was not significantly affected by rs35767 polymorphism (Table 1). Conversely, the rs35767 polymorphism 
exhibited a significant association with serum urate after adjusting for age, gender and BMI in either genetic 
models (Table 1). Notably, the association between the rs35767 polymorphism and serum urate concentrations 
remained significant after further adjusting for glucose tolerance status, and eGFR in addition to age, gender 
and BMI in both an additive (P = 0.05) and a recessive (P = 0.02) genetic model. We observed no statistical dif-
ferences amongst genotype groups in the frequency of anti-hypertensive treatment known to affect urate serum 
concentration, including diuretics, beta-blockers, calcium channel blockers, angiotensin receptor blockers, and 
ACE inhibitors. Accordingly, the association observed between rs35767 genotype and serum urate concentrations 
remained significant after adjusting for anti-hypertensive treatments in addition to age, gender and BMI in both 
an additive (P = 0.03) and a recessive (P = 0.01) genetic model. To estimate the independent contribution of the 
rs35767 polymorphism to serum uric acid levels, we performed a linear regression analysis in a model which also 
included gender, age, and BMI. Comparison of standardized coefficients allowed the determination of the relative 
strength of each trait’s association with serum uric acid levels (listed from strongest to weakest): male gender 
(β = 0.397, P < 0.0001), BMI (β = 0.262, P < 0.0001), age (β = 0.132, P < 0.0001), and the rs35767 polymorphism 
(β = −0.04, P = 0.03).
Twenty-four-hour urinary uric acid concentrations were available for 229 individuals (Table 1). According to 
a recessive genetic model, homozygous carriers of the minor T allele exhibited significantly higher uricosuria in 
comparison to carriers of the major C allele, after correction for age, gender and BMI (Table 1). This association 
remained significant (P = 0.04) after further adjusting for glucose tolerance status, eGFR, and anti-hypertensive 
treatments in addition to age, gender and BMI.
Taken together, these data support our hypothesis that the IGF-1-raising rs35767 polymorphism may con-
tribute to the modulation of serum urate levels by enhancing excretion of uric acid. Therefore, we hypothesized 
that IGF-1 might modulate the expression of uric acid transporters involved in bidirectional renal uric acid han-
dling. To address this issue an in vitro model of Human Embryonic Kidney (HEK293) cells, was used for further 
experiments.
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Effects of IGF-1 on mRNA expression and protein levels of transporters involved in reabsorp-
tion and secretion of uric acid in HEK293 Cells. To gain insight onto the role of IGF-1 on uric acid trans-
porters, HEK293 cells were incubated with increasing physiologic concentration of IGF-1 (1, 5, 10 and 50 nM) 
for 24 hours. As shown in Fig. 1, IGF-1 exposure significantly increased mRNA expression of MRP4, NPT1 and 
BCRP urate transporters (Fig. 1a,c,e, respectively), which mediate uric acid export into urines. The effect of IGF-1 
was dose-dependent with maximal effect occurring at 50 nM IGF-1 (P < 0.01 for all genes). Likewise, IGF-1 expo-
sure significantly increased protein abundance of MRP4, NPT1 and BCRP uric acid transporters as assessed by 
Western blot analyses in whole cell lysates (P < 0.01 for all transporters) (Fig. 1b,d,f, respectively). Conversely, 
treatment of HEK293 cells with IGF-1 resulted in a significant reduction in mRNA expression of GLUT9 (Fig. 2c), 
which is thought to play a major role in the reabsorption of uric acid into the blood and interstitial fluid. Similarly, 
IGF-1 exposure significantly reduced protein abundance of GLUT9 in whole cell lysates (Fig. 2d). No effect of 
IGF-1 was observed on OAT4 and URAT1 uric acid transporters expression either at mRNA or protein level 
(Fig. 2a,b,e,f).
Discussion
There is evidence from genetic22,23,32, and cross-sectional studies24 that the IGF-1/IGF-1 receptor signaling path-
way may have a role in modulating serum urate levels. Prior in vitro and in vivo evidences have consistently 
observed that the genetic variant rs35767, located within the promoter region of IGF1, affects the expression 
levels of IGF-1 and its circulating concentrations, specifically showing that the T allele is the IGF-1 raising pol-
ymorphism26–31. These findings were the premises which led us to formulate the hypothesis that the rs35767 
polymorphism might associate with serum urate concentration. To validate this hypothesis we analyzed over 
2500 clinically and metabolically well-characterized Italian adults and we discovered that individuals carrying 
the TT genotype had significantly reduced serum urate levels when compared with carriers of rs35767 C allele. 
Furthermore, this association persisted when other factors known to affect urate serum concentration, such as 
gender, age, BMI, glucose tolerance status, eGFR, and treatment with anti-hypertensive (diuretics, beta-blockers, 
calcium channel blockers, angiotensin receptor blockers, and ACE inhibitors) were included in the statistical 
model. Interestingly, subjects carrying the TT genotype displayed higher uricosuria with respect to CT and CC 
carriers, after adjusting for confounders. This finding coupled with a previous pilot experimental study show-
ing that acute infusion of IGF-1 reduces serum urate levels in healthy individuals25 prompted us to hypothesize 
IGF-1/IGF-1 receptor signaling pathway might contribute to regulate serum urate by modulating expression of 
uric acid transporters involved in reabsorption and secretion of uric acid in the kidney. In humans, almost all 
serum urate is initially filtered by the kidney but about 90% is reabsorbed into the blood via a complex interplay 
of uric acid transporters located along the proximal tubule35,36. MRP4, NPT1 and BCRP uric acid transporters are 
thought to be involved in uric acid excretion, the URAT1 and OAT4 transporters are involved in apical reabsorp-
tion of uric acid, while GLUT9, is thought to be the major basolateral uric acid transporter in renal tubular cells 
contributing to the reabsorption of uric acid into the blood and interstitial fluid. We found, for the first time, that 
Variables CC CT TT
Padditive model  
(C/C vs. C/T vs. T/T)
Precessive model 
(C/C + C/T vs. T/T)
Female/Male 914/895 436/423 63/63 0.98 0.99
Age (yr) 49.8 ± 13.8 50.4 ± 14.3 50.6 ± 11.4 0.57§ 0.63§
BMI (kg/m2) 30.2 ± 6.4 29.9 ± 6.5 30.0 ± 6.5 0.53* 0.97*
Waist circumference (cm) 100.6 ± 14.8 100.3 ± 15.4 101.1 ± 15.5 0.86* 0.77*
Fasting glucose (mg/dL) 105 ± 35 108 ± 40 104 ± 35 0.06 0.39
2h-plasma glucose (mg/dL) 128 ± 43 127 ± 44 126 ± 47 0.90 0.69
HbA1c (%) [mmol/mol] 5.9 ± 1.2 [41] 6.0 ± 1.5 [42] 6.0 ± 1.3 [41] 0.39 0.87
Systolic blood pressure (mmHg) 130 ± 18 131 ± 18 130 ± 16 0.61 0.32
Diastolic blood pressure (mmHg) 80 ± 11 80 ± 10 80 ± 10 0.74 0.69
Creatinine (mg/dl) 0.81 ± 0.24 0.81 ± 0.24 0.77 ± 0.15 0.13 0.06
eGFR (ml/min/1.73 m2) 100 ± 23 99 ± 24 101 ± 19 0.45 0.22
Uric acid (mg/dL) 5.21 ± 1.41 5.16 ± 1.36 4.90 ± 1.37 0.02 0.007
Urinary uric acid  (mg/dL)
(No. 229 subjects)
37.9 ± 25.8 
(No. = 152)
33.6 ± 26.46 
(No. = 68)
59.1 ± 39.8 
(No. = 9) 0.06 0.03
NGT/IFG/IGT/combo IFG + IGT/T2DM (No.) 901/205/171/131/401 416/89/75/65/214 61/18/10/11/26 0.75 0.73
ACE inhibitor therapy, No.(%) 365 (20.2%) 181 (21.1%) 31 (24.6%) 0.46 0.19
Angiotensin receptor blocker therapy, No.(%) 298 (16.5%) 151 (17.6%) 15 (11.9%) 0.27 0.18
Diuretics, No.(%) 320 (17.7%) 163 (19.0%) 17 (13.5%) 0.30 0.18
Calcium channel blockers, No. (%) 243 (13.4%) 112 (13.0%) 18 (14.3%) 0.91 0.75
Beta blockers, No. (%) 284 (15.7%) 141 (16.4%) 17 (13.5%) 0.68 0.81
Table 1. Clinical characteristics of 2794 study subjects according to the SNP rs35767 near IGF1. Data are as 
means ± SD. Categorical variables were compared by χ2 test. Comparisons between the groups were performed 
using a general linear model. P values refer to results after analyses with adjustment for age, gender, and BMI. 
§P values refer to results after analyses with adjustment for gender. *P values refer to results after analyses with 
adjustment for gender, and age.
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exposure of HEK293 human embryonic kidney cell line to IGF-1 resulted in a dose-dependent increase of MRP4, 
NPT1 and BCRP uric acid transporters at both mRNA and protein level. By contrast, IGF-1 treatment of HEK293 
cells resulted in a significant reduction of GLUT9 expression both at mRNA and protein level. Notably, these 
results were observed using a range of physiological IGF-1 concentrations (5–50 nM or 38–380 ng/mL), thus sug-
gesting that the present findings may be clinically relevant. Overall, these findings provide a mechanistic expla-
nation of the observed association between serum uric acid levels and the IGF-1-raising rs35767 polymorphism 
near the promoter region of the IGF1 gene. However, we cannot rule out the possibility that other mechanisms 
Figure 1. Effect of IGF-1 on urate excretory transporters, mRNA and protein levels. HEK293 cells were 
incubated in presence of increasing IGF-1 concentrations (5, 10, 50 nM). mRNA levels were measured by Real 
Time RT-PCR. (a) MRP4 mRNA levels; (b) MRP4 protein levels; (c) NTP1 mRNA levels; (d) NPT1 protein 
levels; (e) BCRP mRNA levels; (f) BCRP protein levels. Data are means ± SD of three independent experiments, 
each done in triplicate. *P < 0.02 and **P < 0.01 vs. basal. To see the original blots from which these images 
were taken, please refer to the Online Supplementary Information (Supplemental Fig. 1).
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may account for the observed association between serum uric acid levels and the IGF-1-raising rs35767 poly-
morphism. For instance, it has been demonstrated that infusion of recombinant IGF-1 increases GFR in normal 
individuals25 and improves renal function in patients with end-stage chronic renal failure37. Moreover, IGF-1 cir-
culating levels have been associated with eGFR in both hypertensive individuals38 and obese subjects39. Thus, the 
present results may be due to an effect of IGF-1 on renal blood flow and GFR. However, the findings that eGFR 
did not differ among the genotypes, and the observation that rs35767 genotype was still associated to serum urate 
concentrations after adjusting for eGFR argue against the possibility.
Figure 2. Effect of IGF-1 on urate re-absorptive transporters, mRNA and protein levels. HEK293 cells were 
incubated in presence of increasing IGF-1 concentrations (5, 10, 50 nM). mRNA levels were measured by Real 
Time RT-PCR. (a) OAT4 mRNA levels; (b) OAT4 protein levels; (c) GLUT9 mRNA levels; (d) GLUT9 protein 
levels; (e) URAT1 mRNA levels; (f) URAT1 protein levels. Data are means ± SD of three independent experiments, 
each done in triplicate. *P < 0.04, **P < 0.02 and ***P < 0.01 vs. basal. To see the original blots from which these 
images were taken, please refer to the Online Supplementary Information (Supplemental Fig. 2).
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The current report thrives on the relatively large size of the study cohort, which balances gender, considers a 
large spectrum of glucose tolerance, and contemplates an ethnically homogeneous Caucasian group. In addition 
to this, we excluded the presence of chronic conditions potentially affecting both serum uric acid concentra-
tion and circulating IGF-1 and the accurate collection of clinical and biochemical information was employed to 
account for several plausible interferences, together with the centralization of biochemical and analytical assays.
Nonetheless, we need to acknowledge a few limits of our study. Indeed, all biochemical variables, including 
serum urate concentrations and plasma glucose during OGTT were measured once, and because these meas-
urements are subject to intra-individual variability, we cannot exclude that some imprecision in the proportion 
of subjects with abnormal glucose tolerance has been introduced. The 24-hour uricosuria measurement solely 
provides an estimate of the overall output of uric acid; fractional excretion of uric acid would have been a more 
informative index of its overall tubular handling, but we are not in possession of these data at the moment, and 
we encourage future research into the renal kinetics of uric acid. Moreover, these results might only be relevant 
to adult White Europeans, and should not be extended to different ethnicities. Finally, our cohort was enrolled 
while in the context of hospital care, comprising individuals exposed to different grades of cardiometabolic dys-
functions, which means that the present discoveries should not be generalized to healthy subjects. Collectively, 
the current findings ought not to be interpreted as final and need replication in other studies and ethnic groups, 
with independent settings.
In conclusion, these evidences shed new light over the pathophysiological mechanisms connecting the IGF-1 
polymorphism rs35767 and serum urate levels. Our genetic investigation strongly demonstrates that a lifelong 
exposure to lower or higher levels of IGF-1, can modulate uric acid homeostasis at a systemic level. These findings 
underlie the importance of early intervention directed at increasing IGF-1 levels, expecially in at-risk categories. 
Such increment can effectively and physiologically be produced through the implementation of a healthy diet 
plan, exercise and weight loss.
References
 1. Facchini, F., Chen, Y. D., Hollenbeck, C. B. & Reaven, G. M. Relationship between resistance to insulin-mediated glucose uptake, 
urinary uric acid clearance, and plasma uric acid concentration. JAMA. 266, 3008–3011 (1991).
 2. Choi, H. K., Atkinson, K., Karlson, E. W. & Curhan, G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: 
the health professionals follow-up study. ArchInternMed. 165, 742–748 (2005).
 3. Perticone, F. et al. Serum uric acid and 1-h post load glucose in essential hypertension. Diabetes Care. 35, 153–157 (2012).
 4. Choi, H. K. & Ford, E. S. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 120, 442–447 (2007).
 5. Kodama, S. et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 32, 1737–1742 (2009).
 6. Perticone, F. et al. Interaction between uric acid and endothelial dysfunction predicts new onset of diabetes in hypertensive patients. 
Int J Cardiol. 167, 232–236 (2013).
 7. Zoccali, C., Maio, R., Mallamaci, F., Sesti, G. & Perticone, F. Uric acid and endothelial dysfunction in essential hypertension. J Am 
Soc Nephrol JASN. 17, 1466–1471 (2006).
 8. Montalcini, T. et al. A Relation between serum uric acid and carotid intima-media thickness in healthy postmenopausal women. 
Intern Emerg Med. 2, 19–23 (2007).
 9. Fang, J. & Alderman, M. H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. 
National Health and Nutrition Examination Survey. JAMA. 283, 2404–2410 (2000).
 10. Perticone, F. et al. Interaction between uric acid and endothelial dysfunction predicts new onset of diabetes in hypertensive patients. 
Int J Cardiol. 167, 232–236 (2013).
 11. Sciacqua, A. et al. Uric acid is an independent predictor of cardiovascular events in post-menopausal women. Int J Cardiol. 197, 
271–275 (2015).
 12. Hediger, M. A., Johnson, R. J., Miyazaki, H. & Endou, H. Molecular physiology of urate transport. Physiology (Bethesda). 20, 
125–133 (2005).
 13. Yang, Q. et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism. 54, 
1435–1441 (2005).
 14. Nath, S. D. et al. Genome scan for determinants of serum uric acid variability. J. Am. Soc. Nephrol. 18, 3156–3163 (2007).
 15. Li, S. et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet. 3; https://doi.
org/10.1371/journal.pgen.0030194 (2007).
 16. Doring, A. et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat. Genet. 40, 430–436 (2008).
 17. Vitart, V. et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat. 
Genet. 40, 437–442 (2008).
 18. Dehghan, A. et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. 
Lancet. 372, 1953–1961 (2008).
 19. Kolz, M. et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid 
concentrations. PLoS Genet. 5, https://doi.org/10.1371/journal.pgen.1000504 (2009).
 20. Yang, Q. et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk 
factors. Circ. Cardiovasc. Genet. 3, 523–530 (2010).
 21. Woodward, O. M. et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. 
Natl. Acad. Sci. USA 106, 10338–10342 (2009).
 22. Köttgen, A. et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 45, 
145–54 (2013).
 23. Phipps-Green, A. J. et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis 75, 
124–30 (2016).
 24. Sesti, G. et al. Low circulating insulin-like growth factor-1 levels are associated with high serum uric acid in nondiabetic adult 
subjects. Nutr MetabCardiovascDis. 24, 1365–1372 (2014).
 25. Guler, H. P., Schmid, C., Zapf, J. & Froesch, E. R. Effects of recombinant insulin-like growth factor I on insulin secretion and renal 
function in normal human subjects. Proc NatlAcad Sci USA 86, 2868–72 (1989).
 26. Canzian, F. et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of 
IGF-1 and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer. 94, 299–307 (2006).
 27. Palles, C. et al. Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy. HumMolGenet. 17, 
1457–64 (2008).
 28. Patel A.V. et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from 
the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoSOne 3, https://doi.org/10.1371/journal.pone.0002578 (2008).
www.nature.com/scientificreports/
8SCIenTIFIC REPORts |  (2018) 8:12255  | DOI:10.1038/s41598-018-29665-3
 29. Ollberding, N. J. et al. Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the 
risk of colorectal cancer: the Multiethnic Cohort study. Cancer Epidemiol Biomark Prev. 21, 810–20 (2012).
 30. Mannino G. C. et al. A fasting insulin-raising allele at IGF1 locus is associated with circulating levels of IGF-1 and insulin sensitivity. 
PloSOne. 8, https://doi.org/10.1371/journal.pone.0085483 (2013).
 31. Sesti, G. et al. A polymorphism at IGF1 locus is associated with carotid intima media thickness and endothelium-dependent 
vasodilatation. Atherosclerosis. 232, 25–30 (2014).
 32. MacArthur, J. et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids 
Research. 45, D896–D901 (2017).
 33. Marini, M. A. et al. A polymorphism at IGF1 locus is associated with anemia. Oncotarget. 8, 32398–32406 (2017).
 34. Levey, A. S. et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: 
evaluation, classification, and stratification. Ann Intern Med. 139, 137–47 (2003).
 35. Wright, A. F., Rudan, I., Hastie, N. D. & Campbell, H. A ‘complexity’ of urate transporters. Kidney Int. 78, 446–52 (2010).
 36. Merriman, T. R. An update on the genetic architecture of hyperuricemia and gout. Arthritis Res Ther. 17, 98 (2015).
 37. Vijayan, A., Franklin, S. C., Behrend, T., Hammerman, M. R. & Miller, S. B. Insulin-like growth factor 1 improves renal function in 
patients with end-stage chronic renal failure. Am J Physiol. 276, R929–34 (1999).
 38. Perticone, F. et al. Insulin-like growth factor-1 and glomerular filtration rate in hypertensive patients. J Hypertens. 27, 613–7 (2009).
 39. Sesti, G. et al. IGF-1 levels link estimated glomerular filtration rate to insulin resistance in obesity: A study in obese, but metabolically 
healthy, subjects and obese, insulin-resistant subjects. Nutr MetabCardiovasc Dis. 21, 485–491 (2011).
Acknowledgements
This work was supported, in part, by the Foundation for Diabetes Research of the Italian Diabetes Society, 
through the award of “Fondazione Diabete Ricerca FO.DI.RI. - MSD” scholarships in 2014 and 2015 to Gaia 
Chiara Mannino, in part, by the European Community (grant number Medigene-FP7-279171-1) to Giorgio 
Sesti and by the Italian Ministry of University (grant number 2015MPESjS_006) to Giorgio Sesti. The funding 
resources did not take any part in the design of the study, collection, analysis, and interpretation of data, and in 
writing the manuscript.
Author Contributions
G.C.M. and A.F. researched data, reviewed and edited the manuscript; C.D.F., E.M., R.S., M.A.M. researched data; 
G.C.M. and F.P. contributed to the discussion and reviewed the manuscript; F.A. analyzed the data and reviewed 
the manuscript. G.S. designed the study, analyzed the data and wrote the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-29665-3.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
